US nod for Watson's oxybutynin gel 10% for overactive bladder (PharmaBiz) PDF Print

Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, announced that the US Food and Drug Administration (FDA) has approved Gelnique (oxybutynin chloride) gel 10 per cent, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

read more

 
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.